This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 1996 Aug 29;335(9):659-60.

doi: 10.1056/NEJM199608293350910.

Pharmacotherapy for obesity -- do the benefits outweigh the risks?

J E Manson, G A Faich

PMID: 8687523
DOI: 10.1056/NEJM199608293350910

Editorial

Pharmacotherapy for obesity -- do the benefits outweigh the risks?

J E Manson et al. N Engl J Med. 1996.

. 1996 Aug 29;335(9):659-60.

doi: 10.1056/NEJM199608293350910.

Authors

J E Manson, G A Faich

PMID: 8687523
DOI: 10.1056/NEJM199608293350910

No abstract available

PubMed Disclaimer

Comment in

Editorials and conflicts of interest.
Angell M, Kassirer JP. Angell M, et al. N Engl J Med. 1996 Oct 3;335(14):1055-6. doi: 10.1056/NEJM199610033351410. N Engl J Med. 1996. PMID: 8793932 No abstract available.
Editorials and conflicts of interest.
Stone LR. Stone LR. N Engl J Med. 1997 Mar 6;336(10):728; author reply 729. N Engl J Med. 1997. PMID: 9045046 No abstract available.

Comment on

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.
Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Bégaud B. Abenhaim L, et al. N Engl J Med. 1996 Aug 29;335(9):609-16. doi: 10.1056/NEJM199608293350901. N Engl J Med. 1996. PMID: 8692238

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information